Table 2.

Mixed relative treatment effects of major adverse cardiovascular event and composite renal events among urate lowering agents

MACE; RR (95% CI)
Rasburicase	-	-	-
1.69 (0.79, 3.63)	Febuxostat	0.82 (0.52, 1.32)	0.62 (0.35, 1.11)
2.92 (1.25, 6.78)	1.72 (0.94, 3.17)	Allopurinol	0.75 (0.47, 1.21)
1.14 (0.59, 2.22)	0.68 (0.46, 0.99)	0.39 (0.23, 0.66)	Placebo/no ULT
Composite renal events; RR (95% CI)

CI Confidence interval, MACE Major adverse cardiovascular events, RR Risk ratio, ULT, Urate-lowering therapy agents

Comparisons are read from left to right for both MACE and composite renal events. For example; allopurinol had lower composite renal events with RR (95% CI) of 0.39 (0.23, 0.66) compared with placebo/no ULT, and lower MACE with RR (95% CI) of 0.75 (0.47, 1.21) compared with placebo/no ULT

Bold font indicates statistical significance